The 2022 wave com­ing? Top an­a­lyst says Big Phar­ma will have more than $1T avail­able to sat­is­fy its grow­ing ap­petite for biotech M&A

All through this year you could prac­ti­cal­ly feel the frus­tra­tion of the biotech in­vestor class as M&A ac­tiv­i­ty con­tin­ued to drag be­hind ex­pec­ta­tions — or de­sires …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN